INT103043

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2002
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 16
Total Number 18
Disease Relevance 7.79
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
muscle 1
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 26 99.48 Very High Very High Very High
Angina 12 99.36 Very High Very High Very High
nud 16 99.04 Very High Very High Very High
Multiple sclerosis 8 94.36 High High
Central nervous system 17 91.92 High High
adenocard 4 88.96 High High
Glutamate 1 88.56 High High
Neuritis 1 79.12 Quite High
sodium channel 2 74.76 Quite High
Eae 1 73.84 Quite High
Disease Link Frequency Relevance Heat
Vomiting 11 99.52 Very High Very High Very High
Headache 26 99.48 Very High Very High Very High
Cv General 3 Under Development 17 99.36 Very High Very High Very High
Increased Venous Pressure Under Development 83 99.08 Very High Very High Very High
Dyspepsia 16 99.04 Very High Very High Very High
Reprotox - General 2 258 98.86 Very High Very High Very High
Cardiovascular Disease 36 98.72 Very High Very High Very High
Neurodegenerative Disease 21 98.32 Very High Very High Very High
Rhinitis 2 98.12 Very High Very High Very High
Hypogonadotropic Hypogonadism 42 98.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recently, PDE-5 inhibitors have been associated with adverse vision effects, and emerging evidence now indicates that they may also be responsible for hearing changes and hearing loss.
PDE-5 Binding (associated) of associated with deafness
1) Confidence 0.37 Published 2010 Journal Pharmacotherapy Section Abstract Doc Link 20030481 Disease Relevance 1.11 Pain Relevance 0.15
Several lines of evidence indicate that targeting PDE5 with sildenafil offers novel strategies in the treatment of age-related memory impairment.
PDE5 Binding (targeting) of associated with cognitive disorder
2) Confidence 0.37 Published 2007 Journal Pharmacol Rep Section Abstract Doc Link 17556793 Disease Relevance 0.75 Pain Relevance 0.25
For the patients, the factors most significantly associated with treatment preference were differences in time concerns, choice of dose, intercourse satisfaction, number of sexual attempts, satisfaction with erection hardness and the absence of or only minor side effects.19 Although preference studies have shown that all the PDE5 inhibitors were highly effective, the majority of patients seemed to prefer tadalafil because it is easier to take, can be ingested at any time of the day, and its property of enabling them to achieve an erection, with sexual stimulation, long after taking the drug (eg, 8, 16 or 24 hours later), leading to higher sexual self-confidence and spontaneity and fewer time concerns related to sexual encounters.7,19
PDE5 Binding (all) of
3) Confidence 0.37 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778425 Disease Relevance 0.11 Pain Relevance 0
Adverse events associated with vardenafil were those commonly associated with PDE5 inhibitors: headache, flushing, dyspepsia and rhinitis.
PDE5 Binding (associated) of associated with rhinitis, nud, headache and increased venous pressure under development
4) Confidence 0.37 Published 2002 Journal Drugs Aging Section Abstract Doc Link 12027779 Disease Relevance 0.72 Pain Relevance 0.15
The Princeton Consensus Recommendations were developed to provide instructions to physicians who treat men with CVD and ED and answer the most common question: is it safe to take PDE5i and engage in sexual activity?
PDE5i Binding (engage) of associated with reprotox - general 2 and cardiovascular disease
5) Confidence 0.36 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2699643 Disease Relevance 1.01 Pain Relevance 0.13
A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED.
PDE5 Binding (recognized) of associated with reprotox - general 2
6) Confidence 0.36 Published 2009 Journal Patient Prefer Adherence Section Abstract Doc Link PMC2778425 Disease Relevance 0.49 Pain Relevance 0
Of interest, a SNP in PDE5A was associated with BA hyperemic flow velocity in FBAT analyses.
PDE5A Spec (analyses) Binding (associated) of
7) Confidence 0.36 Published 2007 Journal BMC Med Genet Section Body Doc Link PMC1995617 Disease Relevance 0.08 Pain Relevance 0.04
SDS-PAGE Western blot of protein samples from chorionic plate arterial ring homogenates were demonstrated to specifically bind PDE-5 antibody (Figure 2 Panel B).
PDE-5 Binding (bind) of
8) Confidence 0.35 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2680410 Disease Relevance 0 Pain Relevance 0
Fluorescent microscopy of paraffin embedded slices of chorionic plate arterial rings demonstrated specific binding of PDE-5 primary antibodies within the cytoplasm of cells in the muscle layer within the arterial ring section.
PDE-5 Binding (binding) of in muscle
9) Confidence 0.35 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2680410 Disease Relevance 0 Pain Relevance 0
Some PDEs are highly specific for cAMP (PDE4, PDE7, PDE8); others are highly specific for cGMP (PDE5, PDE6, PDE9), and some have mixed specificity (PDE1, PDE2, PDE3, PDE10).
PDE5 Binding (specific) of
10) Confidence 0.31 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.06 Pain Relevance 0
Sildenafil citrate (Viagra®, Pfizer, Inc., New York, NY, U.S.A.) was initially developed as a drug to treat angina, but it was found to be highly specific to PDE5.
PDE5 Binding (specific) of associated with angina
11) Confidence 0.27 Published 2004 Journal Journal of Korean Medical Science Section Body Doc Link PMC2816895 Disease Relevance 0.61 Pain Relevance 0.25
The use of ethanol and PDE-5 inhibitors with sexual activity is recognized.
PDE-5 Binding (recognized) of
12) Confidence 0.26 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936309 Disease Relevance 0.42 Pain Relevance 0.08
Although the clinical efficacy of PDE5I for penile rehabilitation remains open to debate, basic science research has generally indicated favorable outcomes in animal models.69,70 Tadalafil seems a logical choice for rehabilitative therapy given its prolonged duration of action; if indeed PDE5I exerts a protective or salubrious effect on penile tissues, a prolonged duration of exposure seems most likely to produce the desired results.
PDE5I Binding (indeed) of
13) Confidence 0.21 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2939761 Disease Relevance 0.18 Pain Relevance 0
When consulting basic science literature on PDE5I, it is important to recognize that the metabolism of PDE5I in rodents is much more rapid than in humans, and hence, proportionally large doses must be given to determine the therapeutic effects.71
PDE5I Binding (metabolism) of
14) Confidence 0.18 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2939761 Disease Relevance 0.19 Pain Relevance 0
AIM: Evaluate if the association of a phosphodiesterase-5 inhibitor, tadalafil, and a selective serotonin reuptake inhibitor, fluoxetine, can prolong the intravaginal ejaculatory latency time (IELT) in men with lifelong premature ejaculation.
phosphodiesterase-5 Binding (association) of
15) Confidence 0.15 Published 2008 Journal Urol. Int. Section Body Doc Link 18362486 Disease Relevance 0.09 Pain Relevance 0
It is unclear whether PDE5-I, testosterone, or the combination of the two should be started first in men with hypogonadism and ED.45 All men with ED should be screened for hypogonadism before treating for erectile dysfunction.102
PDE5-I Binding (combination) of associated with reprotox - general 2 and hypogonadotropic hypogonadism
16) Confidence 0.09 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2701485 Disease Relevance 1.25 Pain Relevance 0.07
Classical PDE5 inhibitors and selected cyclic nucleotide analogs compete with cGMP at the catalytic site but do not interact with the cGMP-binding allosteric sites (Blount et al 2004).
PDE5 Neg (not) Binding (interact) of
17) Confidence 0.07 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.08 Pain Relevance 0
Current US labeling for sildenafil, tadalafil, and vardenafil states that these phosphodiesterase type 5 inhibitors should be started at the lowest recommended dose for patients stabilized on ?
phosphodiesterase type 5 Binding (these) of
18) Confidence 0.03 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 0.63 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox